logo

For the Inventor, By the Inventor

Hørsholm, Denmark

Alk-Abello A/s

Calculating rank
USPTO Granted Patents = 32

% Expired Patents = 43.8



Trademarks = 3

Forward Citations = 107

Loading Chart...
Loading Chart...

83 inventors (with patents filed for the assignee):

goldMedal Henrik Hugo Jacobi (8 out of 8 patents)

silverMedal Christian Gauguin Houghton (6 out of 6 patents)

bronzeMedal Fernando Juan Vidales (5 out of 5 patents)

4.  Juan Carlos Moreno Segura (5 out of 5 patents)

5.  Stig Aasmul-Olsen (5 out of 6 patents)

6.  Hans-Henrik Ipsen (5 out of 5 patents)

7.  Heather Michelle Webster (4 out of 4 patents)

8.  Jason Daniel Frey (4 out of 4 patents)

9.  Craig T Grass (4 out of 4 patents)

10.  Trena Larissa Repp (4 out of 4 patents)

11.  David Rowles (4 out of 4 patents)

12.  Domingo Barber Hernandez (4 out of 4 patents)

13.  Annette Roemmelmayer Lundegaard (4 out of 4 patents)

14.  Lise Lund Maerkedahl (4 out of 4 patents)

15.  Jan Sondergaard Andersen (4 out of 4 patents)


Core Competencies:
Allergen Dosage Form
Peptide Combinations
Mite Allergen Extract
Pharmaceutical Product
Immunological Activity
Cryogranules
Allergen-Specific Immunotherapy
Enzymatic Activity
Antibody Detection
Dust Mite Allergy
Vaccine Formulations
Quantification of Allergens

32 patents:

1. 12692325 - DISPLACERS OF IGE-FCERI (2026-07-28),
2. 11020527 - Injector comprising a safety pin (2021-06-01),
3. 11013781 - Peptide combinations and uses thereof for treating grass allergy (2021-05-25),
4. 10874736 - Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof (2020-12-29),
5. 10842866 - Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof (2020-11-24),
6. 10471008 - Allergen dosage form (2019-11-12),
7. 10080719 - Allergen dosage form (2018-09-25),
8. 10059751 - Peptide combinations and uses thereof in treating dust mite allergy (2018-08-28),
9. 10023900 - Method for quantification of allergens (2018-07-17),
10. 9657070 - Recombinant allergen (2017-05-23),
11. 9415015 - Allergen dosage form (2016-08-16),
12. 9408805 - Allergen dosage form (2016-08-09),
13. 9265824 - Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof (2016-02-23),
14. 9259464 - Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof (2016-02-16),
15. 9248097 - Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season (2016-02-02),
Company Overview
Alk-Abello A/S is a global leader in the development and manufacture of allergy immunotherapy products. The company specializes in innovative treatments for allergic conditions, including allergic rhinitis and asthma, utilizing advanced research in immunology and biotechnology. Headquartered in Hørsholm, Denmark, Alk-Abello is committed to improving the quality of life for individuals with allergies through effective and safe therapeutic solutions, leveraging its expertise to address unmet medical needs in the allergy field.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

32 Patents

#4 in Hørsholm

#99 in Denmark

#20,712 in the World

Hørsholm, DK
Hørsholm, Denmark

Alk-Abello A/s

Forward Citations = 107

83 inventors:

goldMedal Henrik Hugo Jacobi (8 out of 8 patents)

silverMedal Christian Gauguin Houghton (6 out of 6 patents)

bronzeMedal Fernando Juan Vidales (5 out of 5 patents)

4.  Juan Carlos Moreno Segura (5 out of 5 patents)

5.  Stig Aasmul-Olsen (5 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Alk-Abello A/s. Retrieved from https://idiyas.com/company/alk-abello-a-s

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…